Kratom Addiction: Effects, Signs, Symptoms & Treatment

Kratom is addictive: because mitragynine and 7-hydroxymitragynine activate mu-opioid receptors, regular use produces tolerance and physical dependence, and problematic use meets the diagnostic criteria for a substance use disorder. Tolerance means the original dose stops producing the desired effect, prompting escalation to stronger extracts or more frequent dosing. Dependence means the body adapts to the alkaloids and produces withdrawal symptoms when kratom is reduced or stopped.

The DSM-5-TR contains no kratom-specific diagnosis, so clinicians classify problematic kratom use as "other (or unknown) substance use disorder," applying the same 11 criteria used for every substance — impaired control, social impairment, risky use, tolerance, and withdrawal. Meeting 2 to 3 criteria indicates a mild disorder, 4 to 5 a moderate disorder, and 6 or more a severe disorder. Risk rises with high-dose extracts and daily self-treatment of pain, anxiety, or opioid withdrawal, and co-occurring anxiety or depression drives continued use in many clients. Dependence announces itself through a recognizable set of signs and symptoms.

The signs of kratom addiction combine behavioral escalation, physical changes, and psychological dependence that intensify as daily use continues. Recognizing these markers early allows treatment to begin before withdrawal locks the pattern in place.

Behavioral signs include escalating daily dosing, buying powder or extracts in bulk, timing doses to stave off withdrawal, repeated failed attempts to cut down, and concealing use from family or physicians. Physical signs include constipation, nausea, appetite and weight loss, darkening facial pigmentation (hyperpigmentation), sweating, tremor, constricted pupils, and disrupted sleep. Psychological signs include cravings, irritability between doses, and using kratom to self-medicate chronic pain or opioid cravings — a pattern in which a person transfers dependence from opioids to kratom rather than resolving it. These signs track directly with kratom's dose-dependent effects on the body and brain.

Kratom produces a biphasic, dose-dependent effect profile: low doses (1 to 5 grams of leaf powder) cause stimulant-like alertness and sociability, while higher doses (5 grams and above) cause opioid-like sedation and analgesia. Short-term effects include nausea, dizziness, itching, sweating, dry mouth, constipation, and elevated heart rate. Long-term daily use produces dependence, anorexia and weight loss, facial hyperpigmentation, rare seizures, and documented cases of cholestatic hepatotoxicity — a drug-induced liver injury that impairs bile flow.

Fatal kratom-only drug overdose is uncommon but documented. A CDC MMWR analysis of overdose deaths across 27 states from July 2016 through December 2017 detected kratom in 152 deaths and listed it as a cause of death in 91, and nearly all of those deaths involved additional substances such as fentanyl or benzodiazepines. Combining kratom with opioids, benzodiazepines, or alcohol compounds respiratory depression risk, because each drug suppresses the brainstem's drive to breathe. Product safety adds a separate hazard: in 2018 the FDA and CDC linked a multistate Salmonella outbreak to kratom products and the FDA ordered mandatory recalls of contaminated kratom, illustrating the risks of an unregulated supply. When a dependent person stops using, these effects give way to a predictable withdrawal syndrome.

Kratom withdrawal follows an opioid-like pattern — muscle aches, restlessness, runny nose, sweating, chills, abdominal cramping, diarrhea, insomnia, anxiety, and cravings — but is generally milder than withdrawal from full agonists like heroin or oxycodone. Withdrawal is a genuine physiological syndrome driven by mu-opioid receptor adaptation, not a psychological comedown. Rhinorrhea (runny nose) and lacrimation (watery eyes) mirror the autonomic signs clinicians score in opioid withdrawal.

The timeline is consistent: symptoms begin within 12 to 24 hours of the last dose, peak around days 2 to 4, and physical symptoms resolve over roughly 3 to 7 days, with mood disturbance and insomnia persisting longer in heavy users. People who use concentrated extracts or high daily doses experience more intense withdrawal, and medical supervision improves both comfort and treatment retention. Clinicians manage difficult cases with off-label buprenorphine through Suboxone (buprenorphine-naloxone) treatment, which stabilizes the same receptors kratom occupied. Withdrawal management is the entry point to structured kratom addiction treatment.

Kratom’s active compounds, mitragynine and 7-hydroxymitragynine, are partial agonists at the mu-opioid receptor, while prescription opioids such as oxycodone are full agonists — a pharmacological difference that explains kratom’s reputation as a “safer” opioid alternative and why that reputation is misleading. Partial agonism gives kratom a ceiling effect on respiratory depression that full agonists like oxycodone do not have, one reason kratom overdose deaths are rarer than oxycodone overdose deaths. That ceiling effect does not eliminate the risk: kratom still produces physical dependence, a withdrawal syndrome that mirrors opioid withdrawal, and, at high doses or combined with other substances, has been linked to fatal respiratory depression. Because kratom is unregulated, unstandardized in dose and purity, and not FDA-approved for any medical use, it lacks the safety infrastructure that governs prescription opioids — meaning kratom use disorder is treated with the same evidence-based approach covered next.

Kratom use disorder is treated like opioid use disorder, combining medication support with behavioral therapy, because both conditions arise from the same mu-opioid receptor dependence. No FDA-approved medication exists specifically for kratom, so clinicians prescribe buprenorphine — including buprenorphine-naloxone — off-label, supported by published case reports and case series showing it manages kratom withdrawal and prevents relapse. Clonidine and symptomatic medications add comfort during the acute phase, following the same playbook as opioid addiction treatment and medication-assisted treatment (MAT).

Behavioral therapy carries the long-term work: cognitive behavioral therapy restructures the thoughts driving use, contingency management reinforces verified abstinence with tangible rewards, and relapse prevention builds skills for high-risk situations. Dual-diagnosis care treats the chronic pain, anxiety, or opioid history underneath the kratom use so the original problem does not resurface untreated. Ascend Recovery Center delivers this care across a full outpatient continuum — PHP step-down, an intensive outpatient program (IOP), standard outpatient, and telehealth — so clients move to lower intensity as they stabilize. The first step in that continuum is reaching out for help.

Help for kratom addiction starts with a confidential clinical assessment and free insurance verification — not with quitting abruptly and alone. Stopping suddenly after heavy daily use triggers the full withdrawal syndrome and drives most failed quit attempts, so the safest first step is a structured evaluation by a licensed clinical team.

Ascend Recovery Center is a Joint Commission–accredited, Florida DCF-licensed outpatient behavioral health provider in Palm Beach Gardens serving clients across South Florida. Every client receives an ASAM Criteria evaluation that matches the severity of kratom use to the right level of care, integrated treatment for co-occurring anxiety, depression, or chronic pain, and coordinated medication management from the same clinical team throughout treatment. The admissions team verifies insurance benefits at no cost before treatment begins. Call Ascend Recovery Center at (561) 956-1082 to complete a confidential assessment and start kratom addiction treatment.